Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Heavy Chain Antibody

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Heavy Chain Antibody. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-004498-29 Sponsor Protocol Number: 20190360 Start Date*: 2022-01-13
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor...
    Medical condition: Newly Diagnosed Philadelphia (Ph)-negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Trial now transitioned) SE (Trial now transitioned) AT (Ongoing) FI (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) IT (Ongoing) BE (Trial now transitioned) HU (Ongoing) BG (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002460-29 Sponsor Protocol Number: EASIC30505 Start Date*: 2005-09-12
    Sponsor Name:Rheumazentrum Ruhrgebiet.
    Full Title: An Open Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC...
    Medical condition: Ankylosing spondylitis (AS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000181-39 Sponsor Protocol Number: C0168X84, EU-0108 Start Date*: 2005-08-31
    Sponsor Name:Med. Universitaetsklinik Graz, ao Univ. Professor Dr. med. Thomas C. Wascher
    Full Title: A Prospective Trial of Anti-TNF-a Chimeric Monoclonal Antibody (infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity
    Medical condition: Insulin Resistant Human Obesity
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016703-35 Sponsor Protocol Number: NAPMSv3.2 Start Date*: 2010-01-08
    Sponsor Name:Dansk Multipel Sclerose Center
    Full Title: Natalizumabbehandling af progressiv multipel sklerose
    Medical condition: Secondary progressive multiple sclerosis and primary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063400 Secondary progressive multiple sclerosis LLT
    12.0 10063401 Primary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000838-39 Sponsor Protocol Number: MHE104317 Start Date*: 2007-10-11
    Sponsor Name:GlaxoSmithKline Resaearch and Development Ltd
    Full Title: A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome
    Medical condition: Hypereosinophilic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10048643 Hypereosinophilic syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NO (Completed) BE (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) PL (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008432-82 Sponsor Protocol Number: CP-MGA031-02 Start Date*: 2009-07-01
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Chi...
    Medical condition: Recent-onset type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) ES (Temporarily Halted) SE (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011606-41 Sponsor Protocol Number: CP-MGA031-03 Start Date*: 2009-09-15
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in C...
    Medical condition: Recent-onset type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Prematurely Ended) ES (Temporarily Halted) FI (Completed) GB (Completed) DE (Completed) BE (Completed) PL (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000990-29 Sponsor Protocol Number: IC2011-02 Start Date*: Information not available in EudraCT
    Sponsor Name:INSTITUT CURIE
    Full Title: Multinational européan trial for children with the opsoclonus myoclonus syndrome/dancing eye syndrome.
    Medical condition: Opsoclonus myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in children with and without neuroblastoma (NBpos and NBneg)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10015919 - Eye disorders 10053854 Opsoclonus myoclonus PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) SE (Ongoing) IT (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) ES (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001644-21 Sponsor Protocol Number: MEA115661 Start Date*: 2013-06-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials.
    Medical condition: Subjects with Severe Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) IT (Completed) ES (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-022865-81 Sponsor Protocol Number: ALX-0061-1.1/10 Start Date*: 2011-03-02
    Sponsor Name:Ablynx NV
    Full Title: A phase I/II, multi-center, randomized, double-blind, placebo controlled study, with a single ascending dose part followed by a multiple ascending dose part, evaluating the safety, pharmacokinetics...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-003246-93 Sponsor Protocol Number: D3461C00008 Start Date*: 2016-12-06
    Sponsor Name:Astrazeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in ...
    Medical condition: Systemic Lupus Erythematosus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002457-69 Sponsor Protocol Number: CP-MGA031-01 Start Date*: 2008-12-04
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-C...
    Medical condition: Recent-onset type I diabetes mellitus (T1DM)
    Disease: Version SOC Term Classification Code Term Level
    9.0 10045228 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) CZ (Completed) SE (Completed) GB (Completed) EE (Completed) NL (Completed) LV (Completed) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2006-001182-41 Sponsor Protocol Number: C0168X97 Start Date*: 2007-03-27
    Sponsor Name:Ass.Prof. Petros Sfikakis
    Full Title: Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-over, 32 Weeks Study
    Medical condition: Diabetic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002549-39 Sponsor Protocol Number: Ponatinib-1501 Start Date*: 2020-12-07
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho...
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) CZ (Completed) NL (Ongoing) IT (Ongoing) PL (Completed) PT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002666-76 Sponsor Protocol Number: 200363 Start Date*: 2015-06-17
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma
    Medical condition: Severe Eosinophilic Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002513-27 Sponsor Protocol Number: 200862 Start Date*: 2014-11-19
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic...
    Medical condition: Subjects with severe asthma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) BE (Completed) DE (Completed) CZ (Completed) GR (Completed) EE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005299-36 Sponsor Protocol Number: EXEVIR0101 Start Date*: 2021-04-21
    Sponsor Name:ExeVir Bio BV
    Full Title: A 2-part Clinical Study Including a First-in-Human, Open-label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double-blind, Placebo-controlled Part (Phase 2) to Evaluate the Effica...
    Medical condition: Subjects hospitalised for COVID 19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000314-54 Sponsor Protocol Number: 201312 Start Date*: 2014-04-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 201312: A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial
    Medical condition: Subjects with Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) NL (Completed) ES (Completed) GB (Completed) BE (Completed) CZ (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005971-11 Sponsor Protocol Number: AP101-02 Start Date*: 2021-10-20
    Sponsor Name:AL-S Pharma, AG
    Full Title: A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyot...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003697-32 Sponsor Protocol Number: 204471 Start Date*: 2015-12-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizum...
    Medical condition: Subjects with severe asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) DE (Completed) SE (Completed) FR (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA